Cost-Effectiveness of Telaprevir Plus Peginterferon/Ribavirin (TVR+PR) Versus Peginterferon/Ribavirin (PR) in Treatment-Naïve Genotype 1 Chronic Hepatitis C Patients with F2 Fibrosis in Brazil

Autor:	A.D. Morais, M.L. Pereira
Rok vydání:	2013
Předmět:	medicine.medical_specialty Cost effectiveness business.industry Health Policy Public Health Environmental and Occupational Health medicine.disease PEGINTERFERON/RIBAVIRIN Gastroenterology Telaprevir Therapy naive Chronic hepatitis Fibrosis Internal medicine Genotype medicine business medicine.drug
Zdroj:	Value in Health. 16:A354
ISSN:	1098-3015
DOI:	10.1016/j.jval.2013.08.185
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c63765b9fe3c9dde921e014df2ef458 https://doi.org/10.1016/j.jval.2013.08.185 Zobrazit plný text záznamu Full Text from ScienceDirect